RECKITT Benckiser New Zealand (RBNZ) has been fined $1 million for marketing Nurofen products that misleadingly purported to target specific types of pain.
The NZ action follows a successful prosecution by the Australian Competition and Consumer Commission (PD 29 Apr 16) which resulted in a $6 million fine.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Feb 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Feb 17
